Editorial Board — Medscape Diabetes & Endocrinology

Board Members

  • Harpreet S. Bajaj. MD, MPH
    • Research Associate
      Leadership Sinai Center for Diabetes
      Mount Sinai Hospital
      University of Toronto
      Toronto, Ontario, Canada
      Associate Endocrinologist
      LMC Diabetes & Endocrinology
      Brampton, Ontario, Canada
  • Kenneth D. Burman, MD
    • Professor
      Department of Medicine
      Georgetown University School of Medicine
      Chief Endocrine Section
      Washington Hospital Center
      Washington, DC
  • Aaron R. Chidakel, MD
    • New York University Langone Medical Center
      New York, New York
  • Cyrus V. Desouza, MBBS
    • University of Nebraska Medical Center and Nebraska Medicine
      Omaha, Nebraska
  • Vivian Fonseca, MD
    • Tulane University
      New Orleans, Louisiana
 

Board Member Details

Harpreet S. Bajaj, MD, MPH
Harpreet S. Bajaj, MD, MPH

Research Associate, Leadership Sinai Center for Diabetes, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada; Associate Endocrinologist, LMC Diabetes & Endocrinology, Brampton, Ontario, Canada

Harpreet S. Bajaj, MD, MPH, had disclosed the following relevant financial relationships:
Serve(d) as a consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Merck & Co., Inc.; Novo Nordisk; sanofi-aventis; Janssen Pharmaceutical Products, L.P.
Serve(d) as a speaker or a member of a speakers bureau: Abbott Laboratories; Amgen, Inc.; Boehringer Ingelheim Pharmaceuticals; Janssen Pharmaceutical Products, L.P; Merck & Co., Inc.; Novo Nordisk; sanofi-aventis
Received research grant from: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company; Janssen Pharmaceutical Products, L.P; Merck & Co., Inc.; Novo Nordisk; Pfizer Inc.; sanofi-aventis; Valeant Pharmaceuticals International

Kenneth D. Burman, MD

Professor, Department of Medicine, Georgetown University School of Medicine; Chief Endocrine Section, Washington Hospital Center, Washington, DC

Kenneth D. Burman, MD, has disclosed the following relevant financial relationships:
Serve(d) on the advisory board for: Institut Biochimique SA
Serve(d) as a consultant for: LioTriDev LLC
Received research grant from: AstraZeneca Pharmaceuticals LP; Eisai Inc.; Institut Biochimique SA
Received income in an amount equal to or greater than $250 from: UpToDate; Institut Biochimique SA

Aaron R. Chidakel, MD
Aaron R. Chidakel, MD

Assistant Clinical Professor, New York University Langone Medical Center, New York, New York

Aaron R. Chidakel, MD, has disclosed the following relevant financial relationships:
Serve(d) as a speaker or member of a speakers bureau for: AbbVie, sanofi-aventis, Boehringer Ingelheim Pharmaceuticals, Inc.

Cyrus V. Desouza, MBBS
Cyrus V. Desouza, MBBS

Professor, University of Nebraska Medical Center; Professor & Schulz Professor of Diabetes Research (Division Chief), Nebraska Medicine, Omaha, Nebraska

Cyrus V. Desouza, MBBS, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for: Novo Nordisk

Vivian Fonseca, MD
Vivian Fonseca, MD

Professor of Medicine and Pharmacology; Assistant Dean for Clinical Research; Tullis-Tulane Alumni Chair in Diabetes; Chief, Section of Endocrinology, Tulane University Health Sciences Center, New Orleans, Louisiana

Vivian Fonseca, MD, has disclosed the following relevant financial relationships:
Receive(d) research support (to Tulane): Grants from Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceutical Corporation
Received honoraria for consulting and lectures from: Takeda Pharmaceuticals North American, Inc.; Novo Nordisk; sanofi-aventis; Eli Lilly and Company; AstraZeneca Pharmaceuticals, LP; Intarcia; Asahi

Per-Henrik Groop, MD, DMSc
Per-Henrik Groop, MD, DMSc

Professor of Internal Medicine, University of Helsinki; Chief Physician, Abdominal Center Nephrology, Helsinki University Hospital, Helsinki, Finland

Per-Henrik Groop, MD, DMSc, has disclosed the following relevant financial relationships:
Serve(d) as a global advisory board member for: AbbVie; AstraZeneca Pharmaceuticals, LP; Boehringer Ingelheim Pharmaceuticals, LP; Eli Lilly and Company; Janssen Pharmaceutical Products, LP; Medscape, LLC; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; sanofi-aventis
Serve(d) as a speaker (within the last 6-7 years) for: AstraZeneca Pharmaceuticals, LP; Boehringer Ingelheim Pharmaceuticals, LP; Eli Lilly and Company; Elo Water; Genzyme Corporation; Janssen Pharmaceutical Products, LP; Medscape, LLC; Merck sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; sanofi-aventis
Received research grant (6-7 years ago) from: Eli Lilly and Company; Roche
Received income in an amount equal to or greater than $250 (within the last 6-7 years) from: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Elo Water; Genzyme Corporation; Janssen Pharmaceutical Products, L.P.; Medscape, LLC; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; sanofi-aventis

Simon R. Heller, MB BChir, DM, FRCP
Simon R. Heller, MB BChir, DM, FRCP

Professor of Clinical Diabetes, Department of Oncology and Metabolism, University of Sheffield School of Medicine; Honorary Consultant Physician, Department of Diabetes and Endocrinology, Sheffield Teaching Hospitals Foundation Trust, Sheffield, South Yorkshire, United Kingdom

Simon R. Heller, MB BChir, DM, FRCP, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Eli Lilly and Company; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.
Serve(d) as a speaker or member of a speakers bureau for: Eli Lilly and Company; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.; Merck Sharp & Dohme Corp.; AstraZeneca Pharmaceuticals LP
Received research grant from: Medtronic UK Ltd

Scott Kahan, MD, MPH

Faculty, Department of Health Policy and Management, Johns Hopkins University; Faculty, School of Public Health; Director, National Center for Weight and Wellness, Medical Director, Strategies to Overcome and Prevent (STOP) Obesity Alliance, George Washington University, Washington, DC

Scott Kahan, MD, MPH, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for: Novo Nordisk; Orexigen; Vivus

Anne L. Peters, MD
Anne L. Peters, MD, CDE

Professor, Keck School of Medicine; Director, University of Southern California Westside Center for Diabetes, University of Southern California, Los Angeles, California

Anne L. Peters, MD, has disclosed the following relevant financial relationships:
Serve(d) on the advisory board for: Abbott Diabetes Care; Becton Dickinson; Bigfoot Biomedical; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Lexicon Pharmaceuticals, Inc.; Livongo; Medscape; Merck & Co., Inc.; Novo Nordisk; Omada Health; sanofi-aventis; Science 37
Received research support from: Dexcom; MannKind Corporation
Serve(d) as a member of a speakers bureau for: Novo Nordisk
Received income in an amount equal to or greater than $250 from: Abbott Diabetes Care; Becton, Dickinson and Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; ; Merck & Co., Inc.; Janssen Pharmaceuticals, Inc; Lexicon; Medscape; Novo Nordisk; Omada Health; OptumRx; Perrigo; Roche; sanofi

Arya M Sharma, MD, PhD, DSc (h.c.), FRCPC
Arya M Sharma, MD, PhD, DSc (h.c.), FRCPC

Professor of Medicine, Chair of Obesity Research & Management, University of Alberta; Royal Alexandra Hospital, Weight Wise Clinic, Edmonton, Alberta

Arya M Sharma, MD, PhD, DSc (h.c.), FRCPC, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for: Novo Nordisk; Zalgen Labs; Vivus, Inc.; Takeda Pharmaceuticals North America, Inc.; Ethicon, Inc.
Serve(d) as a speaker or a member of a speakers bureau for: Novo Nordisk; Zalgen Labs; Vivus, Inc.; Takeda Pharmaceuticals North America, Inc.; Ethicon, Inc.

Dace L. Trence, MD
Dace L. Trence, MD

Professor, Department of Medicine; Director, Diabetes Care Center; Director, Endocrine Fellowship, University of Washington, Seattle

Dace Trence, MD, has disclosed the following relevant financial relationships:
Holds stock in: Medtronic, Inc.; Sanofi